Tuesday, December 7, 2021  | 2 Jamadilawal, 1443
Samaa TV
Facebook Twitter Youtube
HOME > Money

AGP gets go-ahead to import Russia’s Sputnik V coronavirus vaccine

It has an efficacy of 91.6%

SAMAA | - Posted: Feb 3, 2021 | Last Updated: 10 months ago
SAMAA |
Posted: Feb 3, 2021 | Last Updated: 10 months ago

Artwork: Trinette Lucas/ SAMAA Digital

Listen to the story
The Drug Regulatory Authority of Pakistan (DRAP) has authorised to import and introduce the Sputnik V vaccine in Pakistan to pharmaceutical company AGP. The AGP stock price on February 2, when the company notified the Pakistan Stock Exchange about the development, increased from Rs132 to Rs134.62. Its price has shown upward movement since January 20 when it was priced at Rs114. “DRAP on February 1 has granted Emergency Use Authorization (EUA) for 'Gam-COVID-Vac' combined vector vaccine to prevent coronavirus infection caused by SARS-CoV-2 virus (‘Sputnik V’ or the ‘vaccine’) to the company,” read an AGP notification on PSX. It added the company has also been authorised to import and introduce the vaccine in Pakistan and it was now making efforts to ensure the availability of sufficient supplies on an emergency basis. The said vaccine has been developed by the Gamaleya National Center of Epidemiology and Microbiology, Russia. According to AGP, this vaccine has been approved by 15 countries including Russia, Hungary, Argentina, and the United Arab Emirates with registrations under way in several other countries. As per the interim clinical study report which is based on the Phase III trials of 21,862 volunteers, the efficacy of Sputnik V has been determined at 91.6%, with 100% efficacy against severe cases of COVID-19. “The vaccine has a good safety profile and in particular, there are no strong allergies caused by the vaccine. This is by far, the most effective COVID-19 vaccine to have received EUA in Pakistan and can be administered to persons aged 18 and above, including persons aged above 60,” the notification said.
FaceBook WhatsApp

The Drug Regulatory Authority of Pakistan (DRAP) has authorised to import and introduce the Sputnik V vaccine in Pakistan to pharmaceutical company AGP.

The AGP stock price on February 2, when the company notified the Pakistan Stock Exchange about the development, increased from Rs132 to Rs134.62. Its price has shown upward movement since January 20 when it was priced at Rs114.

“DRAP on February 1 has granted Emergency Use Authorization (EUA) for ‘Gam-COVID-Vac’ combined vector vaccine to prevent coronavirus infection caused by SARS-CoV-2 virus (‘Sputnik V’ or the ‘vaccine’) to the company,” read an AGP notification on PSX.

It added the company has also been authorised to import and introduce the vaccine in Pakistan and it was now making efforts to ensure the availability of sufficient supplies on an emergency basis.

The said vaccine has been developed by the Gamaleya National Center of Epidemiology and Microbiology, Russia.

According to AGP, this vaccine has been approved by 15 countries including Russia, Hungary, Argentina, and the United Arab Emirates with registrations under way in several other countries.

As per the interim clinical study report which is based on the Phase III trials of 21,862 volunteers, the efficacy of Sputnik V has been determined at 91.6%, with 100% efficacy against severe cases of COVID-19.

“The vaccine has a good safety profile and in particular, there are no strong allergies caused by the vaccine. This is by far, the most effective COVID-19 vaccine to have received EUA in Pakistan and can be administered to persons aged 18 and above, including persons aged above 60,” the notification said.

 
HOME  
 
 
RELATED STORIES

Tell us what you think:

Your email address will not be published.

FaceBook WhatsApp
 
 
 
 

MOST READ
MOST READ
Flydubai wants to operate flights to Skardu
Samsung’s Karachi TV lineup plant starts production
No CNG for Punjab, KP after Sindh and Balochistan
Gold price increases by Rs250 in Pakistan
 
 
 
 
 
About Us   |   Anchor Profiles   |   Online Advertising   |   Contact Us   |   Feedback   |   Apps   |   FAQs   |   Authors   |   Comment Policy
Facebook   |   Twitter   |   Instagram   |   YouTube   |   WhatsApp